TABLE 3.

Pain and Disability Index (PDI) scores during the final week of treatment (per-protocol population n=54)

	Baseline	CR oxycodone/CR naloxone	Placebo	P
Family/home responsibility	6.2±2.1	5.4±2.5*	5.6±2.3†	0.3902
Recreation	7.1±2.5	6.2±2.9*	6.5±3.0	0.3167
Social activity	6.2±2.7	5.4±2.6*	5.8±2.9	0.0815
Occupation	6.9±2.4	5.9±3.0*	6.3±2.9	0.1592
Sexual behaviour	6.7±2.7	5.2±3.2*	5.3±3.3†	0.5419
Self care	4.4±2.7	3.4±2.9*	4.1±2.9	0.0500
Life suport	4.5±2.8	3.0±2.8*	4.0±2.9	0.0190
Total pain and disability index scores	42.0±13.2	34.3±15.6‡	37.5±15.2§	0.0511

Data presented as mean ± SD unless otherwise indicated. There were statistically significant improvements after controlled release (CR) oxycodone/CR naloxone treatment compared with placebo treatment for two items (self care and life support), and the total PDI scores approached statistical significance between treatments (P=0.0511). There were statistically significant improvements from baseline in all seven subscales following treatment with CR oxycodone/CR naloxone (*P<0.0264) and in only two subscales following placebo treatment (^†P≤0.0142). The decreases from baseline for the total PDI scores were 18.7% (^‡P=0.0001) and 10.6% (^§P=0.005) following CR oxycodone/CR naloxone and placebo treatments, respectively